Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 5Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 5Renal Insufficiency 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
melflufen × Clear all
NCT03151811 2024-01-30

OCEAN

Oncopeptides AB

Phase 3 Terminated
495 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT04649060 2023-06-08

LIGHTHOUSE

Oncopeptides AB

Phase 3 Terminated
54 enrolled 21 charts
Plasma cell

Multiple Myeloma

NCT03639610 2023-03-10

BRIDGE

Oncopeptides AB

Phase 2 Terminated
35 enrolled 33 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated
56 enrolled 22 charts
Plasma cell

Multiple Myeloma

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed
157 enrolled 26 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT04115956 2022-03-28

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Oncopeptides AB

Phase 1 Terminated
6 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡